Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Non-Current Assets: 2019-2025

Historic Non-Current Assets for Nurix Therapeutics (NRIX) over the last 5 years, with Aug 2025 value amounting to $81.9 million.

  • Nurix Therapeutics' Non-Current Assets rose 42.24% to $81.9 million in Q3 2025 from the same period last year, while for Aug 2025 it was $81.9 million, marking a year-over-year increase of 42.24%. This contributed to the annual value of $50.0 million for FY2024, which is 16.87% down from last year.
  • According to the latest figures from Q3 2025, Nurix Therapeutics' Non-Current Assets is $81.9 million, which was up 7.40% from $76.2 million recorded in Q2 2025.
  • In the past 5 years, Nurix Therapeutics' Non-Current Assets ranged from a high of $165.7 million in Q4 2021 and a low of $40.2 million during Q3 2023.
  • In the last 3 years, Nurix Therapeutics' Non-Current Assets had a median value of $60.6 million in 2023 and averaged $62.0 million.
  • In the last 5 years, Nurix Therapeutics' Non-Current Assets soared by 181.74% in 2021 and then tumbled by 61.47% in 2023.
  • Quarterly analysis of 5 years shows Nurix Therapeutics' Non-Current Assets stood at $165.7 million in 2021, then plummeted by 40.65% to $98.3 million in 2022, then slumped by 38.87% to $60.1 million in 2023, then dropped by 16.87% to $50.0 million in 2024, then spiked by 42.24% to $81.9 million in 2025.
  • Its last three reported values are $81.9 million in Q3 2025, $76.2 million for Q2 2025, and $51.3 million during Q1 2025.